Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia

B. Cui, L. Chen, S. Zhang, M. Mraz, JF. Fecteau, J. Yu, EM. Ghia, L. Zhang, L. Bao, LZ. Rassenti, K. Messer, GA. Calin, CM. Croce, TJ. Kipps,

. 2014 ; 124 (4) : 546-54.

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15008023

High-level leukemia cell expression of micro-RNA 155 (miR-155) is associated with more aggressive disease in patients with chronic lymphocytic leukemia (CLL), including those cases with a low-level expression of ζ-chain-associated protein of 70 kD. CLL with high-level miR-155 expressed lower levels of Src homology-2 domain-containing inositol 5-phosphatase 1 and were more responsive to B-cell receptor (BCR) ligation than CLL with low-level miR-155. Transfection with miR-155 enhanced responsiveness to BCR ligation, whereas transfection with a miR-155 inhibitor had the opposite effect. CLL in lymphoid tissue expressed higher levels of miR155HG than CLL in the blood of the same patient. Also, isolated CD5(bright)CXCR4(dim) cells, representing CLL that had been newly released from the microenvironment, expressed higher levels of miR-155 and were more responsive to BCR ligation than isolated CD5(dim)CXCR4(bright) cells of the same patient. Treatment of CLL or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhanced sensitivity to BCR ligation, effects that could be blocked by inhibitors to miR-155. This study demonstrates that the sensitivity to BCR ligation can be enhanced by high-level expression of miR-155, which in turn can be induced by crosstalk within the tissue microenvironment, potentially contributing to its association with adverse clinical outcome in patients with CLL.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15008023
003      
CZ-PrNML
005      
20170324072652.0
007      
ta
008      
150306s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2014-03-559690 $2 doi
035    __
$a (PubMed)24914134
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Cui, Bing $u Moores Cancer Center, University of California, San Diego, CA;
245    10
$a MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia / $c B. Cui, L. Chen, S. Zhang, M. Mraz, JF. Fecteau, J. Yu, EM. Ghia, L. Zhang, L. Bao, LZ. Rassenti, K. Messer, GA. Calin, CM. Croce, TJ. Kipps,
520    9_
$a High-level leukemia cell expression of micro-RNA 155 (miR-155) is associated with more aggressive disease in patients with chronic lymphocytic leukemia (CLL), including those cases with a low-level expression of ζ-chain-associated protein of 70 kD. CLL with high-level miR-155 expressed lower levels of Src homology-2 domain-containing inositol 5-phosphatase 1 and were more responsive to B-cell receptor (BCR) ligation than CLL with low-level miR-155. Transfection with miR-155 enhanced responsiveness to BCR ligation, whereas transfection with a miR-155 inhibitor had the opposite effect. CLL in lymphoid tissue expressed higher levels of miR155HG than CLL in the blood of the same patient. Also, isolated CD5(bright)CXCR4(dim) cells, representing CLL that had been newly released from the microenvironment, expressed higher levels of miR-155 and were more responsive to BCR ligation than isolated CD5(dim)CXCR4(bright) cells of the same patient. Treatment of CLL or normal B cells with CD40-ligand or B-cell-activating factor upregulated miR-155 and enhanced sensitivity to BCR ligation, effects that could be blocked by inhibitors to miR-155. This study demonstrates that the sensitivity to BCR ligation can be enhanced by high-level expression of miR-155, which in turn can be induced by crosstalk within the tissue microenvironment, potentially contributing to its association with adverse clinical outcome in patients with CLL.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a antigeny CD5 $x genetika $x metabolismus $7 D018956
650    _2
$a western blotting $7 D015153
650    _2
$a ligand CD40 $x genetika $x metabolismus $7 D023201
650    _2
$a vápník $x metabolismus $7 D002118
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a průtoková cytometrie $7 D005434
650    12
$a regulace genové exprese u leukemie $7 D015973
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x genetika $x mortalita $x patologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a fosfatasy $x genetika $x metabolismus $7 D010744
650    _2
$a prognóza $7 D011379
650    _2
$a messenger RNA $x genetika $7 D012333
650    _2
$a kvantitativní polymerázová řetězová reakce $7 D060888
650    _2
$a receptory antigenů B-buněk $x genetika $x metabolismus $7 D011947
650    _2
$a receptory CXCR4 $x genetika $x metabolismus $7 D019718
650    _2
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    _2
$a signální transdukce $7 D015398
650    _2
$a míra přežití $7 D015996
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a nádorové mikroprostředí $7 D059016
650    _2
$a protein-tyrosinkináza ZAP-70 $x genetika $x metabolismus $7 D051746
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chen, Liguang $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Zhang, Suping $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Mraz, Marek $u Moores Cancer Center, University of California, San Diego, CA; Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic; and.
700    1_
$a Fecteau, Jessie-F $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Yu, Jian $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Ghia, Emanuela M $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Zhang, Ling $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Bao, Lei $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Rassenti, Laura Z $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Messer, Karen $u Moores Cancer Center, University of California, San Diego, CA;
700    1_
$a Calin, George A $u Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, of the CLL Research Consortium.
700    1_
$a Croce, Carlo, $d 1944- $u Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, of the CLL Research Consortium. $7 xx0212031
700    1_
$a Kipps, Thomas J $u Moores Cancer Center, University of California, San Diego, CA;
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 124, č. 4 (2014), s. 546-54
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24914134 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150306 $b ABA008
991    __
$a 20170324072927 $b ABA008
999    __
$a ok $b bmc $g 1065296 $s 890823
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 124 $c 4 $d 546-54 $i 1528-0020 $m Blood $n Blood $x MED00000807
LZP    __
$a Pubmed-20150306
Back

Find record

Citation metrics

Archiving options